Tenax Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Tenax Therapeutics (NASDAQ:TENX) reported Q4 earnings with an EPS of $-11.84, missing estimates by -45.0% against an expected $-8.14. Revenue remained unchanged from the previous year. This follows a quarter where the company beat EPS estimates but saw a 19.0% drop in share price the next day.
March 28, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tenax Therapeutics reported a significant miss in Q4 earnings with an EPS of $-11.84, underperforming estimates by -45.0%. Revenue remained flat compared to last year.
The significant miss in earnings expectations is likely to negatively impact investor sentiment, especially considering the historical context where a previous earnings beat was followed by a substantial drop in share price. The lack of revenue growth further compounds concerns about the company's financial health and growth prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100